Thumbnail

CYSTITIS MARKET - PIPELINE INTELLIGENCE, 2020

Looking to buy the report?

Introduction

According to the National Health Service, cystitis is defined as the inflammation of the bladder, which is usually caused by a bladder infection. A urinary tract infection happens when bacteria enters the urethra or bladder, and begins to multiply, leading to infection. This infection could also happen when the naturally occurring bacteria in the body becomes imbalanced. The bacteria leads to an infection and causes inflammation. There are also other chances of causing cystitis, other than infection. As an example, specific medicines and hygiene products may also cause inflammation. The cystitis can affect anyone, but occurs more in women than men.

The prevalence of urinary tract infections (UTI) is rising each, year and it is estimated that in the United States, approximately 6 million patient visits physicians each year, with UTIs. According to the National Kidney Foundation, it is estimated that one in five women will have at least one UTI in their lifetime. Nearly 20% of women who have a UTI will have another, and 30% of those will have yet another. Given the rising prevalence associated with cystitis, advances are needed for patients worldwide.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Cystitis Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for cystitis indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Cystitis Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
  • In the modern world, the overall prevalence of cystitis is increasing, due to various reasons, and according to the American Urological Association, it is estimated that, 150 million UTIs occur yearly, worldwide, which accounts for approximately USD 6 billion in healthcare expenditures

Key Sponsors in Cystitis Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy